Caffeine and headaches

Article

Abstract

Caffeine is the most widely consumed psychostimulant drug in the world. With intermittent exposures, caffeine may act as a mild analgesic for headache or as an adjuvant for the actions of other analgesics. Chronic repetitive exposures to caffeine increase the risks for development of analgesic-overuse headache, chronic daily headache, and physical dependency. Cessation of caffeine use after chronic exposures leads to a withdrawal syndrome with headache as a dominant symptom. At dosages achieved by common dietary intake, caffeine acts as a potent antagonist of central and peripheral nervous system adenosine receptors. The complex effects of caffeine on headache disorders suggest important roles for adenosine in these disorders and in the induction of caffeine dependency.

References and Recommended Reading

  1. 1.
    Frary CD, Johnson RK, Wang MQ: Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 2005, 105:110–113.PubMedCrossRefGoogle Scholar
  2. 2.
    Barone JJ, Roberts HR: Caffeine consumption. Food Chem Toxicol 1996, 34:119–129.PubMedCrossRefGoogle Scholar
  3. 3.
    Somani SM, Gupta P: Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Ther Toxicol 1988, 26:521–533.PubMedGoogle Scholar
  4. 4.
    Fredholm BB, Battig K, Holmen J, et al.: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharm Rev 1999, 51:83–133.PubMedGoogle Scholar
  5. 5.
    Spiller GA: Caffeine. Boca Raton, FL: CRC Press; 1998.Google Scholar
  6. 6.
    Migliardi JR, Armellino JJ, Friedman M, et al.: Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994, 56:576–586.PubMedGoogle Scholar
  7. 7.
    Lipton RB, Stewart WF, Ryan RE, et al.: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. Arch Neurol 1998, 55:210–217.PubMedCrossRefGoogle Scholar
  8. 8.
    Diener HC, Pfaffenrath V, Pageler L, et al.: The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005, 25:776–787.PubMedCrossRefGoogle Scholar
  9. 9.
    Thithapandha A: Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. J Med Assoc Thai 1989, 72:562–566.PubMedGoogle Scholar
  10. 10.
    Iqbal N, Ahmad B, Janbaz KH, et al.: The effect of caffeine on the pharmacokinetics of acetaminophen in man. Biopharm Drug Dispos 1995, 16:481–487.PubMedCrossRefGoogle Scholar
  11. 11.
    Laska EM, Sunshine A, Mueller F, et al.: Caffeine as an analgesic adjuvant. JAMA 1984, 251:1711–1718.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang WY: A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 2001, 24:1127–1142.PubMedCrossRefGoogle Scholar
  13. 13.
    Ward N, Whitney C, Avery D, Dunner D: The analgesic effects of caffeine in headache. Pain 1991, 44:151–155.PubMedCrossRefGoogle Scholar
  14. 14.
    Diamond S, Balm TK, Freitag FG: Ibuprofen plus caffeine in the treatment of tension-type headache. Clin Pharmacol Ther 2000, 68:312–319.PubMedCrossRefGoogle Scholar
  15. 15.
    Camann WR, Murray RS, Mushlin PS, Lambert DH: Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg 1990, 70:181–184.PubMedCrossRefGoogle Scholar
  16. 16.
    Yucel A, Ozyalcin S, Talu GK, et al.: Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med 1999, 24:51–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Esmaoglu A, Akpinar H, Uqur F: Oral multidose caffeineparacetamol combination is not effective for the prophylaxis of postdural puncture headache. J Clin Anesth 2005, 17:58–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Dodick DW, Mosek AC, Campbell JK: The hypnic (“alarm clock”) headache syndrome. Cephalalgia 1998, 18:152–156.PubMedCrossRefGoogle Scholar
  19. 19.
    Dreisbach RH, Pfeiffer C: Caffeine-withdrawal headache. J Lab Clin Med 1943, 28:1212–1219.Google Scholar
  20. 20.
    Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109–1114.PubMedGoogle Scholar
  21. 21.
    Juliano LM, Griffiths RR: A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004, 176:1–29.CrossRefGoogle Scholar
  22. 22.
    The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004, 24(Supp 1):1–160.Google Scholar
  23. 23.
    Evans SM, Griffiths RR: Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 1999, 289:285–294.PubMedGoogle Scholar
  24. 24.
    Fennelly M, Galletly DC, Purdie GI: Is caffeine withdrawal the mechanism of postoperative headache? Anesth Analg 1991, 72:449–453.PubMedCrossRefGoogle Scholar
  25. 25.
    Kendler KS, Prescott CA: Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am J Psychiatry 1999, 156:223–228.PubMedGoogle Scholar
  26. 26.
    Courturier EGM, Hering R, Steiner TJ: Weekend attacks in migraine patients: caused by caffeine withdrawal? Cephalalgia 1992, 12:99–100.CrossRefGoogle Scholar
  27. 27.
    Mosek A, Korczyn AD: Yom Kippur headache. Neurology 1995, 45:1953–1955.PubMedGoogle Scholar
  28. 28.
    Sjaastad O, Bakketeig LS: Caffeine-withdrawal headache. The Vaga study of headache epidemiology. Cephalalgia 2004, 24:241–249.PubMedCrossRefGoogle Scholar
  29. 29.
    Usmani OS, Belvisi MG, Patel HJ, et al.: Theobromine inhibits sensory nerve activation and cough. FASEB J 2005, 19:231–233.PubMedGoogle Scholar
  30. 30.
    Kallenborn R, Weigel S, Jensen E, Hühnerfuss H: Pharmaceutical residues in the northern Norwegian environment. Geological Society of America Abstracts with Programs 2003, 35:143.Google Scholar
  31. 31.
    Griffiths RR, Chausmer AL: Caffeine as a model drug of dependence: recent developments in understanding caffeine withdrawal, the caffeine dependence syndrome, and caffeine negative reinforcement. Jpn J Neuropsychopharmacol 2000, 20:223–231.Google Scholar
  32. 32.
    Hughes JR, Oliveti AH, Liguori A, et al.: Endorsement of DSM-IV dependence criteria among caffeine users. Drug Alcohol Depend 1998, 52:99–107.PubMedCrossRefGoogle Scholar
  33. 33.
    Satel S: Is caffeine addictive? A review of the literature. Am J Drug Alcohol Abuse 2006, 32:493–502.PubMedCrossRefGoogle Scholar
  34. 34.
    Feinstein AR, Heinemann LAJ, Dalessio D, et al.: Do caffeinecontaining analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000, 68:457–467.PubMedCrossRefGoogle Scholar
  35. 35.
    Daly JW, Fredholm BB: Caffeine—an atypical drug of dependence. Drug Alcohol Depend 1998, 51:199–206.PubMedCrossRefGoogle Scholar
  36. 36.
    Schuh KJ, Griffiths RR: Caffeine reinforcement: the role of withdrawal. Psychopharmacology (Berl) 1997, 130:320–326.CrossRefGoogle Scholar
  37. 37.
    Rogers PJ, Martin J, Smith C, et al.: Absence of reinforcing, mood and psychomotor performance effects of caffeine in habitual non-consumers of caffeine. Psychopharmacology (Berl) 2003, 167:54–62.Google Scholar
  38. 38.
    Shirlow MJ, Mathers CD: A study of caffeine consumption and symptoms: indigestion, palpitations, tremor, headache and insomnia. Int J Epidemiol 1985, 14:239–248.PubMedCrossRefGoogle Scholar
  39. 39.
    Boardman HF, Thomas E, Millson DS, Croft PR: Psychological, sleep, lifestyle, and comorbid associations with headache. Headache 2005, 45:657–669.PubMedCrossRefGoogle Scholar
  40. 40.
    Takeshima T, Ishizaki K, Fukuhara Y, et al.: Populationbased door-to-door survey of migraine in Japan: the Daisen study. Headache 2004, 44:1–12.CrossRefGoogle Scholar
  41. 41.
    Bigal M, Sheftell FD, Rapoport AM, et al.: Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42:575–581.PubMedCrossRefGoogle Scholar
  42. 42.
    Scher AI, Stewart WF, Lipton RB: Caffeine as a risk factor for chronic daily headache. Neurology 2004, 63:2022–2027.PubMedGoogle Scholar
  43. 43.
    Wiendels NJ, Knuistingh NA, Rosendaal FR, et al.: Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 2006, 26:1434–1442.PubMedCrossRefGoogle Scholar
  44. 44.
    Hering-Hanit R, Gadoth N: Caffeine-induced headache in children and adolescents. Cephalalgia 2003, 23:332–335.PubMedCrossRefGoogle Scholar
  45. 45.
    Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24:31–55.PubMedCrossRefGoogle Scholar
  46. 46.
    Mathew RJ, Wilson WH: Caffeine induced changes in cerebral circulation. Stroke 1985, 16:814–817.PubMedGoogle Scholar
  47. 47.
    Burnstock G: Pathophysiology of migraine: a new hypothesis. Lancet 1981, 1:1397–1399.PubMedCrossRefGoogle Scholar
  48. 48.
    Burnstock G: The role of adenosine triphosphate in migraine. Biomed Pharmacother 1989, 43:727–736.PubMedCrossRefGoogle Scholar
  49. 49.
    Wolff HG: Headache and Other Pain. Oxford: Oxford University Press; 1948.Google Scholar
  50. 50.
    Guieu R, Devaux C, Henry H, et al.: Adenosine and migraine. Can J Neurol Sci 1998, 25:55–58.PubMedGoogle Scholar
  51. 51.
    Brown SG, Waterer GW: Migraine precipitated by adenosine. Med J Aust 1995, 162:389–391.PubMedGoogle Scholar
  52. 52.
    Hawkes CH: Dipyridamole in migraine. Lancet 1978, 2:153.PubMedCrossRefGoogle Scholar
  53. 53.
    Hardebo JE, Edvinsson L: Adenine compounds: cerebrovascular effects in vitro with reference to their possible involvement in migraine. Stroke 1979, 10:58–62.PubMedGoogle Scholar
  54. 54.
    Conlay LA, Conant JA, deBros F, Wurtman R: Caffeine alters plasma adenosine levels. Nature 1997, 389:136–137.PubMedCrossRefGoogle Scholar
  55. 55.
    Couturier EGM, Laman DM, van Duijn MAJ, van Duijn H: Infl uence of caffeine and caffeine withdrawal on headache and cerebral blood velocities. Cephalalgia 1997, 17:188–190.PubMedCrossRefGoogle Scholar
  56. 56.
    Jones HE, Herning RI, Cadet JL, Griffiths RR: Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity. Psychopharmacology (Berl) 2000, 147:371–377.CrossRefGoogle Scholar
  57. 57.
    Field AS, Laurienti PJ, Yen Y-F, et al.: Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies. Radiology 2003, 227:129–135.PubMedCrossRefGoogle Scholar
  58. 58.
    Fredholm BB: Adenosine actions and adenosine receptors after 1 week treatment with caffeine. Acta Physiol Scand 1982, 115:283–286.PubMedCrossRefGoogle Scholar
  59. 59.
    Johansson B, Georgiev V, Lindstrom K, Fredholm BB: A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 1997, 762:153–164.PubMedCrossRefGoogle Scholar
  60. 60.
    Varani K, Portaluppi F, Merighi S, et al.: Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 1999, 99:2499–2502.PubMedGoogle Scholar
  61. 61.
    Jacobson KA, von Lubitz DKJE, Daly JW, Fredholm BB: Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996, 17:108–113.PubMedCrossRefGoogle Scholar
  62. 62.
    Taiwo YO, Levine JD: Further confirmation of the role of adenylyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991, 44:131–135.PubMedCrossRefGoogle Scholar
  63. 63.
    Santicioli P, Del Bianco E, Maggi CA: Adenosine A1 receptors mediate the presynaptic inhibition of calcitonin gene-related peptide release by adenosine in the rat spinal cord. Eur J Pharmacol 1993, 231:139–142.PubMedCrossRefGoogle Scholar
  64. 64.
    Carruthers AM, Sellers LA, Jenkins DW, et al.: Adenosine A1 receptor-mediated inhibition of protein kinase Ainduced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol 2001, 59:1533–1541.PubMedGoogle Scholar
  65. 65.
    Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 2000, 21:341–346.PubMedCrossRefGoogle Scholar
  66. 66.
    Hohoff C, Marziniak M, Lesch KP, et al.: An adenosine A2A receptor gene haplotype is associated with migraine with aura. Cephalalgia 2007, 27:177–181PubMedCrossRefGoogle Scholar
  67. 67.
    Ghelardini C, Galeotti N, Bartolini A: Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:590–595.PubMedCrossRefGoogle Scholar
  68. 68.
    Sawynok J, Reid A: Neurotoxin-induced lesions to central serotonergic, noradrenergic and dopaminergic systems modify caffeine-induced antinociception in the formalin test and locomotor stimulation in rats. J Pharmacol Exp Ther 1996, 277:646–653.PubMedGoogle Scholar
  69. 69.
    Garrett BE, Griffiths RR: The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav 1997, 57:533–541.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of Neurology, Given C219BUniversity of Vermont College of MedicineBurlingtonUSA

Personalised recommendations